The Clinical Significance of Endocannabinoids in Endometriosis Pain Management Jerome Bouaziz, Alexandra Bar On, Daniel S. Seidman, and David Soriano Cannabis and Cannabinoid Research, 2017, 2, 1, 72-80 DOI : 10.1089/can.2016.0035 Abstract Introduction : Patients with endometriosis often suffer from diffuse and poorly localized severe pain. The current pain management strategies include medical and hormonal therapy, as well as surgery. Medical management of pain is often insufficient and is associated with high rate of recurrence. Better pain management is therefore of urgent need. Methods : Among the various candidates, the endocannabinoid system (ECS) has recently emerged as a relevant pharmacological target for themanagement of endometriosis-related pain. [...]
Lire la suiteUTILISATION DU DRONABINOL (MARINOL ®) EN FRANCE Dr Sarah Lejczak AH, CETD, CHU Nantes sarah.lejczak@chu-nantes.fr 20.06.2019 Utilisation du Marinol en France : enquête auprès des prescripteurs Sarah Lejczak CHU de Nantes Sarah Lejczak, médecin algologue, rappelle qu’il est possible de prescrire du Marinol depuis 2006. Le premier essai clinique sur le cannabis thérapeutique a été réalisé au XIXe siècle, avec des patients atteints de choléra et de tétanos. Ces essais ont été suivis de dérives et de périodes de prohibition. Fort heureusement, des équipes de chercheurs se sont de nouveau emparées de ce sujet à partir des années 1970. Aux États-Unis, l’approche de ce sujet diverge selon les États. [...]
Lire la suiteHow effective and safe is medical cannabis as a treatment of mental disorder ? A systematic review HOCH E., NIEMANN D., von KELLER R., SCHNEIDER M., FRIEMEL C.M., PREUSS U.W., HASAN A., POGARELL O. European Archives of Psychiatry and Clinical Neuroscience, 2019 https://doi.org/10.1007/s00406-019-00984-4 Abstract We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general social anxiety, posttraumatic stress disorder, anorexia nervosa, [...]
Lire la suiteLong-lasting analgesic effect of the psychedelic drug changa : A case report Genis ONA and Sebastian TRONCOSO Journal of Psychedelic Studies, 2019, 3, (1), 7–13. DOI: 10.1556/2054.2019.001 Background and aims : Pain is the most prevalent symptom of a health condition, and it is inappropriately treated in many cases. Here, we present a case report in which we observe a long-lasting analgesic effect produced by changa, a psychedelic drug that contains the psychoactive N,N-dimethyltryptamine and ground seeds of Peganum harmala, which are rich in β-carbolines. Methods : We describe the case and offer a brief review of supportive findings. Results : A long-lasting analgesic effect after [...]
Lire la suiteA Cross-Sectional Study of Cannabidiol Users Jamie Corroon and Joy A. Phillips Cannabis and Cannabinoid Research, 2018, 3, 1, 152-161. https://doi.org/10.1089/can.2018.0006 Abstract Introduction: Preclinical and clinical studies suggest that cannabidiol (CBD) found in Cannabis spp. has broad therapeutic value. CBD products can currently be purchased online, over the counter and at Cannabis-specific dispensaries throughout most of the country, despite the fact that CBD is generally deemed a Schedule I controlled substance by the U.S. Drug Enforcement Administration and renounced as a dietary supplement ingredient by the U.S. Food and Drug Administration. Consumer demand for CBD is high and growing, but few studies have examined the [...]
Lire la suitePsychedelic drugs in the treatment of anxiety, depression and addiction Tor-Morten Kvam, Lowan H. Stewart & Ole A. Andreassen Tidsskriftet, Den Norske Legeforening, November 2018 https://www.researchgate.net/publication/332136512 B A C K G R O U N D There is growing interest in the use of psychedelic drugs for the treatment of mental disorders. The drugs are considered safe when administered within a clinical framework. Older studies performed prior to 1970 had methodological shortcomings, but studies in recent years have shown promising results regarding the use of psychedelic drugs in unipolar depression, depression in life-threatening illness, anxiety and addiction. The aim of this literature review is to [...]
Lire la suiteCannabinol and Neuropathic Pain P.W. Brownjohn and J.C. Ashton Neuropathic Pain, 2012, chap. 4, 79-102 1. Introduction Cannabinoids are drugs that are either derived from cannabis or that induce similar behavioural and physiological effects to cannabis. They fall into three classes: those that are produced by plants of the Cannabis genus, termed phytocannabinoids (plant cannabinoids); those that are produced within the body, termed endocannabinoids (endogenous cannabinoids); and those that are produced synthetically to mimic the pharmacology of naturally occurring cannabinoids. Cannabinoids stand in relation to cannabis as opioids such as codeine, pethidine, fentanyl, and methadone stand in relation to opium. While opium and opioids [...]
Lire la suitePatient Counseling Guidelines for the Use of Cannabis for the Treatment of Chemotherapy-Induced Nausea/Vomiting and Chronic Pain Patrick Makary, Jayesh R. Parmar, Natalie Mims, Nile M. Khanfar and Robert A. Freeman JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2019 https://doi.org/10.1080/15360288.2019.1598531 ABSTRACT The use of cannabis medications has grown in recent years for the symptomatic relief of chemotherapy-induced nausea/vomiting (CINV) and chronic pain (cancer-related and noncancer-related). As states legalize the use of cannabis, it is important for pharmacists and other health care professionals to beaware of how to counsel patients receiving prescriptions for cannabis medications. The aim of this study was to develop patient counseling guidelines [...]
Lire la suiteA Review of Cannabis in Chronic Kidney Disease Symptom Management Claudia Ho, Dan Martinusen, and Clifford Lo2,4,5 Canadian Journal of Kidney Health and Disease, 2019, Volume 6, 1–14 DOI: 10.1177/2054358119828391 journals.sagepub.com/home/cjk Abstract Purpose of Review : Physical and psychological symptom burden in patients with advanced chronic kidney disease (CKD) is significantly debilitating; yet, it is often inadequately treated. Legalization of cannabis in Canada may attract increasing interest from patients for its medical use in refractory symptom management, but its indications and long-term adverse health impacts are poorly established, creating a challenge for clinicians to support its use. In this review, we summarize key clinical studies and [...]
Lire la suiteMedical Cannabis : Effects on Opioid and Benzodiazepine Requirements for Pain Control. Megan O’Connell, PharmD, Megan Sandgren, PharmD, MS, BCPS, Leah Frantzen, PharmD, BCPS, Erika Bower, PharmD, BCACP, Brian Erickson, MD Annals of Pharmacotherapy, 2019 May 25:1060028019854221. doi: 10.1177/1060028019854221. PMID : 31129977 Abstract BACKGROUND : There is currently little evidence regarding the use of medical cannabis for the treatment of intractable pain. Literature published on the subject to date has yielded mixed results concerning the efficacy of medical cannabis and has been limited by study design and regulatory issues. OBJECTIVE: The objective of this study was to determine if the use of medical [...]
Lire la suite